Lupin has informed that it enclosed a Press Release as regards, the Company having signed a license and supply agreement with Sino Universal Pharmaceuticals, for the commercialization of Tiotropium Dry Powder Inhaler, 18 mcg/capsule, in the Chinese market, for the treatment of chronic obstructive pulmonary disease.
The above information is a part of company’s filings submitted to BSE.